Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

BACKGROUND: Nivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue h...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, Pierpaolo, Saladino, Rita Emilena, Giannarelli, Diana, Giannicola, Rocco, Agostino, Rita, Staropoli, Nicoletta, Strangio, Alessandra, Del Giudice, Teresa, Nardone, Valerio, Altomonte, Maria, Pastina, Pierpaolo, Tini, Paolo, Falzea, Antonia Consuelo, Imbesi, Natale, Arcati, Valentina, Romeo, Giuseppa, Caracciolo, Daniele, Luce, Amalia, Caraglia, Michele, Giordano, Antonio, Pirtoli, Luigi, Necas, Alois, Amler, Evzen, Barbieri, Vito, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304840/
https://www.ncbi.nlm.nih.gov/pubmed/32554614
http://dx.doi.org/10.1136/jitc-2020-000733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304840/
https://www.ncbi.nlm.nih.gov/pubmed/32554614
http://dx.doi.org/10.1136/jitc-2020-000733

Ejemplares similares